Status:
UNKNOWN
Follow-up With CT-FFR in CHD Patients After DCB
Lead Sponsor:
Beijing Hospital
Collaborating Sponsors:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Peking Union Medical College
Conditions:
Coronary; Ischemic
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
In recent years, based on CCTA data, CT-derived fractional flow reserve (CT-FFR) developed by artificial intelligence and other technologies can provide both anatomical and functional information of c...
Detailed Description
Drug-coated balloon (DCB) intervention is a non-drug treatment of coronary heart disease with the advantage of "no implantation". In recent years, it is more and more used in primary coronary artery d...
Eligibility Criteria
Inclusion
- Be able to understand the purpose of the test and sign the informed consent form.
- 6-12 months after DCB for coronary heart disease, there is no contraindication of coronary artery CTA examination.
- Non-target lesions of unplanned revascularization within 6 months.
- According to the clinical manifestations and auxiliary examinations (such as EET, SPECT, CCTA), the attending doctor will make a comprehensive judgment on the patients who plan to undergo ICA.
Exclusion
- Patient exclusion criteria:
- Previous coronary artery bypass (CABG) surgery, coronary artery stent implantation, artificial heart valve implantation, cardiac pacemaker or implantable defibrillator implantation.
- Persistent or active symptoms of clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure (systolic blood pressure less than 90 mmHg), severe congestive heart failure (NYHA heart function III or IV) or acute pulmonary edema.
- Acute myocardial infarction occurred within 7 days before selection.
- Patients with other severe diseases are not suitable to participate in clinical trials, such as history of complex congenital heart disease, sick sinus syndrome, long QT syndrome, severe arrhythmia or tachycardia, severe asthma, severe or extremely severe chronic obstructive pulmonary disease, chronic renal dysfunction (serum creatinine level \> 2.0mg / dl or creatinine clearance \< 30ml/ Kg ·1.73m2).
- Allergic to iodinated contrast medium.
- Other serious allergic diseases such as allergic asthma.
- Pregnancy or pregnancy status unknown.
- Life expectancy is less than 6 months.
- There are any factors that other researchers think are not suitable for selection or completion of this study.
- \-
- CCTA image exclusion criteria:
- Obvious dislocation of coronary artery image.
- CCTA images indicate that the reference vessel diameter of the stenotic segment is less than 2.0mm.
- The image of coronary artery calcification accounting for more than 80% of the cross-sectional area of the lumen.
- The standard deviation of CT value (SD value) of aortic root image was higher than that of 30HU.
- Coronary artery occlusion.
- The CT-FFR measurement can not be completed due to the quality problem of the image file.
- The clinical trial could not be completed and no effective data were obtained due to other reasons.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT04664439
Start Date
June 1 2021
End Date
June 30 2024
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Hospital
Beijing, China